🔗 Share this article

As the United States continues making historic adjustments to its vaccine schedules, a particular individual appears in a surprising turn: Høeg, a Danish American sports physician and public health researcher who rose to prominence by questioning COVID-19 vaccinations throughout the global health crisis and has concentrated on alleged fatalities following COVID-19 immunization in her recent tenure at the Food and Drug Administration.

Scheduled Changes to Childhood Immunization Schedule

Agency leaders were set to unveil radical revisions to the pediatric immunization program recently, synchronizing the US with the Danish national calendar, sources say – a major change that would place the US out of alignment with many the international standard with no evidence for benefit. The announcement has been delayed until the next year.

Rather than the top vaccines chief, Høeg is set to speak at the meeting. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth person to run the center this calendar year.

A Shift at the FDA

Høeg's temporary position may indicate a closer partnership between the drug and biologics centers as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it suggests a increased emphasis upon rolling back long-standing vaccines at the FDA.

The new acting director has often pushed for ending some childhood vaccine recommendations in the US so as to align more like Denmark's approach, a country with comprehensive healthcare and a population roughly the size of the state of Wisconsin.

To date public appearances, she has persisted in emphasizing on vaccination policy – usually the domain of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Concerns Over Expertise

Høeg has little discernible experience in medication creation, regulation or administrative roles, which has been customary for former directors of the CBER. She has worked at the FDA as a top consultant to the FDA chief and CBER since spring.

“She doesn’t seem to have the requisite experience” for overseeing the CDER, said Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in running a large organization. She has no expertise in drug approvals.”

Previous heads of CBER would “grasp laws and regulations and the science of pharmaceutical innovation”, commented a former acting FDA commissioner. “Objectively, she has not acquired the sort of resume that prior appointees who headed CBER have had.”

CDER has an immense portfolio at the agency, Woodcock pointed out.

“Many people just pays attention on the innovative therapies, but the generic program authorizes numerous generic drugs. There is also a biosimilars program, over-the-counter program and so forth, and each of these must be supervised,” Woodcock said. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Additionally, a substantial administrative element to the job, which manages over 5,000 employees. “It is a enormous leadership role, if you perform it correctly,” Woodcock concluded.

Response and Controversial Policies

When asked about questions about Dr. Høeg's fitness for the role and whether this assignment indicates greater collaboration among FDA leaders on vaccines, a press secretary responded that the “concerns are based on incorrect premises”.

“Her experience aligns with the duties of her position,” the representative said, pointing to the period Dr. Høeg spent counseling the FDA commissioner on “medication safety and approval science, including computerized risk analysis and shot safety tracking”.

As acting director, Dr. Høeg assumes responsibility for the agency head's recently launched priority voucher program, a controversial one-day drug-approval program that apparently concerned her predecessors. “By what process are these medications being chosen for this fast-track system? Who takes the calls?” Howard questioned. “There is a lot of confidentiality going on at the regulatory body right now.”

Overall, he said, “the Food and Drug Administration seems to be moving towards laxer oversight of most medications, except for immunizations.”

Documented Past Work on Immunizations

Concerning immunizations, Høeg has a clearer, if problematic, past, critics have noted. She authored a study using non-validated crowd-sourced reports to assess the frequency of heart inflammation following COVID-19 immunization. She advised the Florida chief medical officer Joseph Ladapo, who reportedly have altered data to suggest Covid vaccinations are pose a greater threat than they are.

Part of her “wish list” for the incoming government encompassed revising regulations for novel immunizations and halting “unnecessary” immunizations, she remarked following the vote on a podcast. At the FDA, Dr. Høeg has allegedly proposed preventing teenage boys from getting Covid vaccines.

“She is an complete dogmatist who starts off with her beliefs and reverse-engineers to fit the data in a very misleading, untruthful way,” Howard argued.

Taking Control and a “Campaign of Retribution”

Høeg joined fellow skeptics, {like|